Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤채옥 | - |
dc.date.accessioned | 2018-08-10T06:07:00Z | - |
dc.date.available | 2018-08-10T06:07:00Z | - |
dc.date.issued | 2016-07 | - |
dc.identifier.citation | JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, v. 35, Page. 1-16 | en_US |
dc.identifier.issn | 1756-9966 | - |
dc.identifier.uri | https://jeccr.biomedcentral.com/articles/10.1186/s13046-016-0353-8 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/74415 | - |
dc.description.abstract | Background: Gene-based virotherapy mediated by oncolytic viruses is currently experiencing a renaissance in cancer therapy. However, relatively little attention has been given to the potentiality of dual gene virotherapy strategy as a novel therapeutic approach to mediate triplex anticancer combination effects, particularly if the two suitable genes are well chosen. Both tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and interleukin-12 (IL-12) have been emerged as promising pharmacological candidates in cancer therapy; however, the combined efficacy of TRAIL and IL-12 genes for treatment of human hepatocellular carcinoma (HCC) remains to be determined. Methods: Herein, we investigated the therapeutic efficacy of concurrent therapy with two armed oncolytic adenoviruses encoding human TRAIL gene (Ad-Delta B/TRAIL) and IL-12 gene (Ad-Delta B/IL-12), respectively, on preclinical models of human HCC, and also elucidated the possible underlying mechanisms. The effects of Ad-Delta B/TRAIL+Ad-Delta B/IL-12 combination therapy were assessed both in vitro on Hep3B and HuH7 human HCC cell lines and in vivo on HCC-orthotopic model established in the livers of athymic nude mice by intrahepatic implantation of human Hep3B cells. Results: Compared to therapy with non-armed control Ad-Delta B, combined therapy with Ad-Delta B/TRAIL+Ad-Delta B/IL-12 elicited profound anti-HCC killing effects on Hep3B and HuH7 cells and on the transplanted Hep3B-orthotopic model. Efficient viral replication and TRAIL and IL-12 expression were also confirmed in HCC cells and the harvested tumor tissues treated with this combination therapy. Mechanistically, co-therapy with Ad-Delta B/TRAIL+Ad-Delta B/IL-12 exhibited an enhanced effect on apoptosis promotion, activation of caspase-3 and-8, generation of anti-tumor immune response evidenced by upregulation of interferon gamma (IFN-gamma) production and infiltration of natural killer-and antigen presenting cells, and remarkable repression of intratumor vascular endothelial growth factor (VEGF) and cluster of differentiation 31 (CD31) expression and tumor microvessel density. Conclusions: Overall, our data showed a favorable therapeutic effect of Ad-Delta B/TRAIL+Ad-Delta B/IL-12 combination therapy against human HCC, and may therefore constitute a promising and effective therapeutic strategy for treating human HCC. However, further studies are warranted for its reliable clinical translation. | en_US |
dc.description.sponsorship | This project was funded by the National Science, Technology and Innovation Plan (MARRIFAH)-King Abdul Aziz City for Science and Technology (KACST), the Kingdom of Saudi Arabia, Award Number (11-MED2065-10). | en_US |
dc.language.iso | en | en_US |
dc.publisher | BIOMED CENTRAL LTD | en_US |
dc.subject | Dual gene virotherapy | en_US |
dc.subject | Oncolytic adenoviruses | en_US |
dc.subject | Interleukin-12 | en_US |
dc.subject | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) | en_US |
dc.subject | Hepatocellular carcinoma | en_US |
dc.title | Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model | en_US |
dc.type | Article | en_US |
dc.relation.volume | 35 | - |
dc.identifier.doi | 10.1186/s13046-016-0353-8 | - |
dc.relation.page | 1-1 | - |
dc.relation.journal | JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | - |
dc.contributor.googleauthor | El-Shemi, Adel Galal | - |
dc.contributor.googleauthor | Ashshi, Ahmad Mohammed | - |
dc.contributor.googleauthor | Na, Youjin | - |
dc.contributor.googleauthor | Li, Yan | - |
dc.contributor.googleauthor | Basalamah, Mohammed | - |
dc.contributor.googleauthor | Al-Allaf, Faisal Ahmad | - |
dc.contributor.googleauthor | Oh, Eonju | - |
dc.contributor.googleauthor | Jung, Bo-Kyeong | - |
dc.contributor.googleauthor | Yun, Chae-Ok | - |
dc.relation.code | 2016007987 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF ENGINEERING[S] | - |
dc.sector.department | DEPARTMENT OF BIOENGINEERING | - |
dc.identifier.pid | chaeok | - |
dc.identifier.orcid | http://orcid.org/0000-0002-9466-4531 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.